BackImunon Overview

Imunon Current Cash

Track Imunon's current cash ($4.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$4.79M

Peer average

Loading

Imunon Current Cash History

Loading

Imunon vs. peers: Current Cash Comparison

Loading

Imunon Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Imunon (IMNN) FAQ

The latest current cash for IMNN is $4.8M as of March 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Imunon's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMNN's current cash moved from $0 to $4.8M. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Imunon's operating scale or balance-sheet position.

A current cash figure of $4.8M for IMNN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IMNN's current cash ($4.8M), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Imunon's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.